Treatment approaches aim to restore or mimic p53's function in cells where it has gone awry. For example, scientists have developed small molecules that can bind to mutant p53 and stabilize its ...

Australian researchers have discovered that a single mutation in the DNA sequence for a methylation enzyme dysregulates key ...

Australian researchers have discovered that a single mutation in the DNA sequence for a methylation enzyme dysregulates key ...

When analyzing the p53 sequence, she noticed that it looked similar to many other known transcription factors. “At the time, my first hypothesis was it was a transcriptional repressor,” Lozano ...

Sustained reactivation of mutant p53 drives durable anti-tumor activity across models, including KRAS co-mutant tumors FMC-220 selectively stabilizes p53 Y220C at lower doses, overcoming key ...

It is involved in the development and commercialization of novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company was founded by Vladimir Bykov, Klas Gota Wiman ...

FMC-220 is designed to address the potency and durability challenges seen with non-covalent approaches targeting the structurally destabilized p53 Y220C mutant. Preclinical studies showed FMC-220 ...